Eloxx Pharmaceuticals in the spotlight (part IV)

Data delays and upcoming catalysts

Following up on our previous Eloxx (ELOX) posts (part I, part II, and part III), the company reported Q3 business updates last week, which caused the stock to trade lower, presumably because combination data was pushed back from Q1 2022 – mid-2022. Monotherapy data for Phase 2 ELX-02 in cystic fibrosis patients is still expected in Q4 2021, albeit later…